Dmitrii S. Bezrukov

Dmitrii S. Bezrukov

Auto-generated profile, based on publicly available information

Dmitrii S. Bezrukov

Department of Chemistry, M.V. Lomonosov Moscow State University, Moscow 119991, Russia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
YIYan A. Ivanenkov
Yan A. Ivanenkov
MVMark S. Veselov
Mark S. Veselov
IRIgor G. Rezekin
Igor G. Rezekin
DSDmitry Skvortsov
Dmitry Skvortsov
YSYuri B. Sandulenko
Yuri B. Sandulenko
AMAlexander G. Majouga
Alexander G. Majouga

19 February 2020 in ChemRxiv
Verified
Preprint
Open access
AZAlex Zhavoronkov
Alex Zhavoronkov
VAVladimir Aladinskiy
Vladimir Aladinskiy
AZAlexander Zhebrak
Alexander Zhebrak
BZBogdan Zagribelnyy
Bogdan Zagribelnyy
VTVictor Terentiev
Victor Terentiev
YIYan Ivanenkov
Yan Ivanenkov
The emergence of the 2019 novel coronavirus (COVID-19), for which there is no vaccine or any known effective treatment created a sense of urgency for novel drug discovery approaches. One of the most important COVID-19 protein targets is the 3C-like protease for which the crystal structure is known. Most of the immediate efforts are focused on drug repurposing of known clinically-approved drugs and virtual screening for the molecules available from chemical libraries that may not work well. For example, the IC50 of lopinavir, an HIV protease inhibitor, against the 3C-like protease is approximately 50 micromolar, which is far from ideal. In an attempt to address this challenge, on January 28th, 2020 Insilico Medicine decided to utilize a part of its generative chemistry pipeline to design novel drug-like inhibitors of COVID-19 and started generation on January 30th. It utilized three of its previously validated generative chemistry approaches: crystal-derived pocked-based generator, homology modelling-based generation, and ligand-based generation. Novel druglike compounds generated using these approaches were published at www.insilico.com/ncov-sprint/. Several molecules will be synthesized and tested using the internal resources; however, the team is seeking collaborations to synthesize, test, and, if needed, optimize the published molecules.

10 February 2020 in ChemRxiv
Verified
Preprint
Open access
AZAlex Zhavoronkov
Alex Zhavoronkov
VAVladimir Aladinskiy
Vladimir Aladinskiy
AZAlexander Zhebrak
Alexander Zhebrak
BZBogdan Zagribelnyy
Bogdan Zagribelnyy
VTVictor Terentiev
Victor Terentiev
YIYan Ivanenkov
Yan Ivanenkov
The emergence of the 2019 novel coronavirus (2019-nCoV), for which there is no vaccine or any known effective treatment created a sense of urgency for novel drug discovery approaches. One of the most important 2019-nCoV protein targets is the 3C-like protease for which the crystal structure is known. Most of the immediate efforts are focused on drug repurposing of known clinically-approved drugs and virtual screening for the molecules available from chemical libraries that may not work well. For example, the IC50 of lopinavir, an HIV protease inhibitor, against the 3C-like protease is approximately 50 micromolar. In an attempt to address this challenge, on January 28th, 2020 Insilico Medicine decided to utilize a part of its generative chemistry pipeline to design novel drug-like inhibitors of 2019-nCoV and started generation on January 30th. It utilized three of its previously validated generative chemistry approaches: crystal-derived pocked- based generator, homology modelling-based generation, and ligand-based generation. Novel druglike compounds generated using these approaches are being published at www.insilico.com/ncov-sprint/ and will be continuously updated. Several molecules will be synthesized and tested using the internal resources; however, the team is seeking collaborations to synthesize, test, and, if needed, optimize the published molecules.

19 May 2020 in ChemRxiv
Verified
Preprint
Open access
PDF file
AZAlex Zhavoronkov
Alex Zhavoronkov
BZBogdan Zagribelnyy
Bogdan Zagribelnyy
AZAlexander Zhebrak
Alexander Zhebrak
VAVladimir Aladinskiy
Vladimir Aladinskiy
VTVictor Terentiev
Victor Terentiev
YIYan Ivanenkov
Yan Ivanenkov
One of the most important SARS-CoV-2 protein targets for therapeutics is the 3C-like protease (main protease, Mpro). In our previous work1​we used the first Mpro crystal structure to become available, 6LU7. On February 4, 2020 Insilico Medicine released the first potential novel protease inhibitors designed using a ​de novo,​AI-driven generative chemistry approach. Nearly 100 X-ray structures of Mpro co-crystallized both with covalent and non-covalent ligands have been published since then. Here we utilize the recently published 6W63 crystal structure of Mpro complexed with a non-covalent inhibitor and combined two approaches used in our previous study: ligand-based and crystal structure-based. We published 10 representative structures for potential development with 3D representation in PDB format and welcome medicinal chemists for broad discussion and generated output analysis. The molecules in SDF format and PDB-models for generated protein-ligand complexes are available here and at https://insilico.com/ncov-sprint/.​Medicinal chemistry VR analysis was provided by ​Nanome team and the video of VR session is available at ​https://bit.ly/ncov-vr.​

6 November 2015 in The Journal of Chemical Physics
Verified
Journal Article
Closed access
PDF file
LTL.-G. Tao
L.-G. Tao
NKN. N. Kleshchina
N. N. Kleshchina
RLR. Lambo
R. Lambo
ABA. A. Buchachenko
A. A. Buchachenko
XZX.-G. Zhou
X.-G. Zhou
Shui-Ming HuShui-Ming Hu
Shui-Ming Hu
The low-lying electronic states of Yb isolated in a solid Ar matrix grown at 4.2 K are characterized through absorption and emission spectroscopy. Yb atoms are found to occupy three distinct thermally stable trapping sites labeled “red,” “blue,” and “violet” according to the relative positions of the absorption features they produce. Classical simulations of the site structure and relative stability broadly reproduced the experimentally observed matrix-induced frequency shifts and thus identified the red, blue, and violet sites as due to respective single substitutional (ss), tetravacancy ( tv ), and hexavacancy ( hv ) occupation. Prolonged excitation of the 1S → 1P transition was found to transfer the Yb population from hv sites into tv and ss sites. The process showed reversibility in that annealing to 24 K predominantly transferred the tv population back into hv sites. Population kinetics were used to deduce the effective rate parameters for the site transformation processes. Experimental observations indicate that the blue and violet sites lie close in energy, whereas the red one is much less stable. Classical simulations identify the blue site as the most stable one.

28 September 2019 in The Journal of Chemical Physics
Verified
Journal Article
Open access
PDF file
NKNadezhda N. Kleshchina
Nadezhda N. Kleshchina
IKInna S. Kalinina
Inna S. Kalinina
ILIosif V. Leibin
Iosif V. Leibin
DBDmitry S. Bezrukov
Dmitry S. Bezrukov
ABAlexei A. Buchachenko
Alexei A. Buchachenko
Closed-shell metal atoms in rare gas solids tend to occupy highly symmetric polyhedral crystal sites, as follows from the generic triplet Jahn-Teller splitting of the S → P excitation bands and complies with the isotropic nature of the dispersion forces. Atypical 2 + 1 Jahn-Teller splitting inherent to axially symmetric sites observed recently for Ba atoms has been therefore interpreted as the defect accommodation. By modeling the structure, stability, and spectra of the Ba atom in the face-centered cubic rare gas crystals, we identify thermodynamically stable crystal site of axial C3v symmetry that explains experimental observations. We also demonstrate the dramatic effect of the interaction anisotropy on the trapping site structure and stability for an excited P-state atom. Our results provide strong evidence for stable axially symmetric accommodation of isotropic impurity in a close-packed lattice.